RxDoctor Payments Data

Zachary Cohen, MD

Family Medicine · Decatur, GANPI 1356630586

Payments from drug & device makers

$1,840in general payments, 2019–2025

Across 76 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$545
  • AbbVie$302
  • Lilly USA, LLC$192
  • AstraZeneca$178
  • Inspire Medical Systems, Inc.$108
  • Exact Sciences$78
  • plus $437 from 14 others

What the payments were for

  • Food & beverage$1,72494%
  • Education$1166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,840 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$16,289
Medicare patients
42
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$41,802
MounjaroTirzepatide22$34,592
RybelsusSemaglutide18$27,637
Breo ElliptaFluticasone/Vilanterol13$5,756
Mirtazapine16$704
Atorvastatin Calcium57$558
Amlodipine Besylate51$469
Albuterol Sulfate HfaAlbuterol Sulfate24$380
Nifedipine ErNifedipine19$339
Duloxetine Hcl14$336
Metoprolol Succinate15$297
Lisinopril44$225
Losartan Potassium40$213
Levothyroxine Sodium24$198
Zolpidem Tartrate24$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$545$69,43851 claims
Lilly USA, LLCMounjaro$192$34,59222 claims
GSKBreo Ellipta$66$5,75613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →